Case of Acute B cell Lymphoblastic Leukaemia in HIV-infected patient with chronic hepatitis C

Purpose. To observe clinical course of acute B cell lymphoblastic leukaemia and HIV infection combination from the point of view of current treatment conceptions for thus patients.Materials and methods. A clinical case of acute B cell lymphoblastic leukaemia in HIV-infected patient is presented.Results and discussion. 39-year old HIV-infected male with acute B cell lymphoblastic leukaemia received chemotherapy with the ALL-2009 regimen simultaneously with anti-retroviral therapy accompanied by severe leukopenia complicated with pneumonia by the force of strong comorbidity resulting to lethal outcome.Summary. Nowadays acute B cell lymphoblastic leukaemia and HIV infection combination that predestine poor prognosis in the accordance of special infection and immune status within the comorbidity of the patients, what demands to establish particular guidelines for chemotherapy, target therapy, maintenance treatment and bone marrow stem cell transplantation to improve efficiency of therapeutic inﬂuence at the course of heamoblastosis, so as HIV infection.

Download Full-text

Faculty Opinions recommendation of Inadequate T follicular cell help impairs B cell immunity during HIV infection.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.717988314.793514509 ◽

2016 ◽

Author(s):

Warren J Leonard

Keyword(s):

Hiv Infection ◽

B Cell ◽

Follicular Cell ◽

Cell Immunity ◽

B Cell Immunity

Download Full-text

Faculty Opinions recommendation of Inadequate T follicular cell help impairs B cell immunity during HIV infection.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.717988314.793476387 ◽

2013 ◽

Author(s):

Gerrit Koopman

Keyword(s):

Hiv Infection ◽

B Cell ◽

Follicular Cell ◽

Cell Immunity ◽

B Cell Immunity

Download Full-text

Faculty Opinions recommendation of Prognostic effect of chromosomal abnormalities in childhood B-cell precursor acute lymphoblastic leukaemia: results from the UK Medical Research Council ALL97/99 randomised trial.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.718430955.793495858 ◽

2014 ◽

Author(s):

Jacob Rowe ◽

Tsila Zuckerman

Keyword(s):

Acute Lymphoblastic Leukaemia ◽

B Cell ◽

Lymphoblastic Leukaemia ◽

Research Council ◽

Medical Research Council ◽

Chromosomal Abnormalities ◽

Randomised Trial ◽

Cell Precursor ◽

Prognostic Effect ◽

The Uk

Download Full-text

Faculty Opinions recommendation of Signalling thresholds and negative B-cell selection in acute lymphoblastic leukaemia.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.725402302.793515695 ◽

2016 ◽

Author(s):

Michael Farrar

Keyword(s):

Acute Lymphoblastic Leukaemia ◽

B Cell ◽

Lymphoblastic Leukaemia ◽

Cell Selection

Download Full-text

CKLF and IL1B transcript levels at diagnosis are predictive of relapse in children with pre‐B‐cell acute lymphoblastic leukaemia

British Journal of Haematology ◽

10.1111/bjh.17161 ◽

2021 ◽

Vol 193 (1) ◽

pp. 171-175

Author(s):

Stephen Fitter ◽

Alanah L. Bradey ◽

Chung Hoow Kok ◽

Jacqueline E. Noll ◽

Vicki J. Wilczek ◽

...

Keyword(s):

Acute Lymphoblastic Leukaemia ◽

B Cell ◽

Lymphoblastic Leukaemia ◽

Transcript Levels

Download Full-text

Different Microfluidic Environments for In Vitro Testing of Lipid Nanoparticles against Osteosarcoma

Bioengineering ◽

10.3390/bioengineering8060077 ◽

2021 ◽

Vol 8 (6) ◽

pp. 77

Author(s):

Oihane Mitxelena-Iribarren ◽

Sara Lizarbe-Sancha ◽

Jay Campisi ◽

Sergio Arana ◽

Maite Mujika

Keyword(s):

Target Therapy ◽

Treatment Options ◽

Lipid Nanoparticles ◽

Cell Number ◽

Current Treatment ◽

Drug Dose ◽

Free Drug ◽

Tumor Treatment ◽

Equal Dose

The use of lipid nanoparticles as biodegradable shells for controlled drug delivery shows promise as a more effective and targeted tumor treatment than traditional treatment methods. Although the combination of target therapy with nanotechnology created new hope for cancer treatment, methodological issues during in vitro validation of nanovehicles slowed their application. In the current work, the effect of methotrexate (MTX) encapsulated in different matrices was evaluated in a dynamic microfluidic platform. Effects on the viability of osteosarcoma cells in the presence of recirculation of cell media, free MTX and two types of blank and drug-containing nanoparticles were successfully assessed in different tumor-mimicking microenvironments. Encapsulated MTX was more effective than the equal dose free drug treatment, as cell death significantly increased under the recirculation of both types of drug-loaded nanoparticles in all concentrations. In fact, MTX-nanoparticles reduced cell population 50 times more than the free drug when 150-µM drug dose was recirculated. Moreover, when compared to the equivalent free drug dose recirculation, cell number was reduced 60 and 100 points more under recirculation of each nanoparticle with a 15-µM drug concentration. Thus, the results obtained with the microfluidic model present MTX-lipid nanoparticles as a promising and more effective therapy for pediatric osteosarcoma treatment than current treatment options.

Download Full-text